Closing Out With KRAS and HER2 Advances in NSCLC

, ,

Thoracic Night Live | <b>Reflections on the Pivotal Lung Cancer Data of 2021</b>

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD; conclude this series by discussing encouraging data and updates in non–small cell lung cancer treatment for patients who harbor KRAS and HER2 abnormalities.

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD, conclude this series by discussing encouraging data and updates in non–small cell lung cancer treatment for patients who harbor KRAS and HER2 abnormalities.

Funding from Daiichi Sankyo/Content Independently Developed by OncLive